Literature DB >> 1879958

Therapeutic activities of antibiotics in listeriosis.

H Hof1.   

Abstract

In vitro practically all common antibiotics except cephalosporins are active against nearly all natural isolates of Listeria monocytogenes; the therapeutic efficacy of antibiotic treatment is, however, rather limited, since up to 30% listeriosis patients will succumb to this infection. At least one reason for this low in vivo efficiency is the intracellular habitat of L. monocytogenes. In animal experiments ampicillin or amoxicillin, respectively, are still the most active drugs. In addition, rifampicin also has pronounced protective activity. Coumermycin, which unfortunately cannot be given to humans, is the most reliable drug in animals.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1879958     DOI: 10.1007/bf01644039

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  29 in total

1.  The effect of coumermycin on experimental listeriosis.

Authors:  H Hof
Journal:  J Infect       Date:  1986-07       Impact factor: 6.072

2.  Intracellular microorganisms: a particular problem for chemotherapy. Introduction.

Authors:  H Hof
Journal:  Infection       Date:  1991       Impact factor: 3.553

3.  Treatment of experimental listeriosis by CI 934, a new quinolone.

Authors:  H Hof
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

4.  Therapeutic activity of teicoplanin on experimental listeriosis compared with that of vancomycin and ampicillin.

Authors:  R Berner; H Hof
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1988-03

5.  Lack of synergism of ampicillin and gentamicin in experimental listeriosis.

Authors:  H Hof; H Gückel
Journal:  Infection       Date:  1987 Jan-Feb       Impact factor: 3.553

6.  Evaluation of rifampin and other antibiotics against Listeria monocytogenes in vitro and in vivo.

Authors:  W M Scheld
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

7.  Murine model for therapy of listeriosis in the compromised host. III. The effect of rifampicin.

Authors:  H Hof; P Emmerling
Journal:  Chemotherapy       Date:  1984       Impact factor: 2.544

8.  Uptake and activity of rifapentine in human peritoneal macrophages and polymorphonuclear leukocytes.

Authors:  A Pascual; D Tsukayama; J Kovarik; G Gekker; P Peterson
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267

9.  Transferable plasmid-mediated antibiotic resistance in Listeria monocytogenes.

Authors:  C Poyart-Salmeron; C Carlier; P Trieu-Cuot; A L Courtieu; P Courvalin
Journal:  Lancet       Date:  1990-06-16       Impact factor: 79.321

10.  Murine model for therapy of listeriosis in the compromised host. IV. Cotrimoxazole.

Authors:  B Kawaler; H Hof
Journal:  Chemotherapy       Date:  1985       Impact factor: 2.544

View more
  6 in total

Review 1.  Antibiotic resistance in Listeria spp.

Authors:  E Charpentier; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  Spinal manifestation of neurolisteriosis.

Authors:  K Pfadenhauer; T Rossmanith
Journal:  J Neurol       Date:  1995-02       Impact factor: 4.849

3.  Inhibition of intracellular growth of Listeria monocytogenes by antibiotics.

Authors:  C Michelet; J L Avril; F Cartier; P Berche
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 4.  Antimicrobial chemotherapy of human infection due to Listeria monocytogenes.

Authors:  E M Jones; A P MacGowan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

5.  In vitro study of synergy of ampicillin with ceftriaxone against Listeria monocytogenes.

Authors:  J A Lepe; A Rodríguez-Villodres; G Martín-Gutiérrez; R Luque; J Aznar
Journal:  Rev Esp Quimioter       Date:  2019-09-12       Impact factor: 1.553

Review 6.  Infectious disease: how to manage Gram-positive and Gram-negative pathogen conundrums with dual beta-lactam therapy.

Authors:  Alireza FakhriRavari; Brenda Simiyu; Taylor Morrisette; Yewande Dayo; Jacinda C Abdul-Mutakabbir
Journal:  Drugs Context       Date:  2022-01-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.